166 related articles for article (PubMed ID: 37122191)
21. Pharmacokinetic/pharmacodynamic drug evaluation of benralizumab for the treatment of asthma.
Matera MG; Calzetta L; Rinaldi B; Cazzola M
Expert Opin Drug Metab Toxicol; 2017 Sep; 13(9):1007-1013. PubMed ID: 28737051
[TBL] [Abstract][Full Text] [Related]
22. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
[TBL] [Abstract][Full Text] [Related]
23. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
24. Exploring the risk of infection events in patients with asthma receiving
Giossi R; Pani A; Schroeder J; Scaglione F
Heliyon; 2024 Jan; 10(1):e23725. PubMed ID: 38268596
[TBL] [Abstract][Full Text] [Related]
25. Reslizumab Compared with Benralizumab in Patients with Eosinophilic Asthma: A Systematic Literature Review and Network Meta-Analysis.
Casale TB; Pacou M; Mesana L; Farge G; Sun SX; Castro M
J Allergy Clin Immunol Pract; 2019 Jan; 7(1):122-130.e1. PubMed ID: 30217529
[TBL] [Abstract][Full Text] [Related]
26. Eosinophils in bullous pemphigoid.
Jones VA; Patel PM; Amber KT
Panminerva Med; 2021 Sep; 63(3):368-378. PubMed ID: 32536149
[TBL] [Abstract][Full Text] [Related]
27. Benralizumab--a humanized mAb to IL-5Rα with enhanced antibody-dependent cell-mediated cytotoxicity--a novel approach for the treatment of asthma.
Ghazi A; Trikha A; Calhoun WJ
Expert Opin Biol Ther; 2012 Jan; 12(1):113-8. PubMed ID: 22136436
[TBL] [Abstract][Full Text] [Related]
28. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
[TBL] [Abstract][Full Text] [Related]
29. Characteristics of patients with bullous pemphigoid: comparison of classic bullous pemphigoid to non-bullous pemphigoid.
Ben Mordehai Y; Faibish H; Astman N; Greenberger S; Barzilai A; Baum S
J Eur Acad Dermatol Venereol; 2020 Jan; 34(1):161-165. PubMed ID: 31423677
[TBL] [Abstract][Full Text] [Related]
30. Benralizumab: an updated treatment of eosinophilic asthma.
Cushen B; Menzies-Gow A
Expert Rev Respir Med; 2020 May; 14(5):435-444. PubMed ID: 32133878
[No Abstract] [Full Text] [Related]
31. Asthma Control, Airway Mucus, and
McIntosh MJ; Kooner HK; Eddy RL; Jeimy S; Licskai C; Mackenzie CA; Svenningsen S; Nair P; Yamashita C; Parraga G
Chest; 2022 Sep; 162(3):520-533. PubMed ID: 35283104
[TBL] [Abstract][Full Text] [Related]
32. Targeting the Interleukin-5 Pathway for Treatment of Eosinophilic Conditions Other than Asthma.
Roufosse F
Front Med (Lausanne); 2018; 5():49. PubMed ID: 29682504
[TBL] [Abstract][Full Text] [Related]
33. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):1-8. PubMed ID: 31136278
[TBL] [Abstract][Full Text] [Related]
34. Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment.
Ujiie I; Iwata H; Yoshimoto N; Izumi K; Shimizu H; Ujiie H
J Dermatol; 2021 Apr; 48(4):502-510. PubMed ID: 33600037
[TBL] [Abstract][Full Text] [Related]
35. [Benralizumab: Targeting the IL-5 Receptor in Severe Eosinophilic Asthma].
Leuppi JD; Schmid-Grendelmeier P; Rothe T; von Garnier C; Simon HU; Schuoler C; Pendl G; Solèr M
Praxis (Bern 1994); 2019; 108(7):469-476. PubMed ID: 31136272
[TBL] [Abstract][Full Text] [Related]
36. Bullous pemphigoid: interaction of interleukin 5, anti-basement membrane zone antibodies and eosinophils. A preliminary observation.
Engineer L; Bhol K; Kumari S; Razzaque Ahmed A
Cytokine; 2001 Jan; 13(1):32-38. PubMed ID: 11145840
[TBL] [Abstract][Full Text] [Related]
37. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
[TBL] [Abstract][Full Text] [Related]
38. Benralizumab: an anti-IL-5 receptor α monoclonal antibody in the treatment of asthma.
Kupczyk M; Kuna P
Immunotherapy; 2018 Apr; 10(5):349-359. PubMed ID: 29359607
[TBL] [Abstract][Full Text] [Related]
39. Eosinophils as putative therapeutic targets in bullous pemphigoid.
Simon D; Borradori L; Simon HU
Exp Dermatol; 2017 Dec; 26(12):1187-1192. PubMed ID: 28833620
[TBL] [Abstract][Full Text] [Related]
40. Benralizumab for the treatment of asthma.
Saco TV; Pepper AN; Lockey RF
Expert Rev Clin Immunol; 2017 May; 13(5):405-413. PubMed ID: 28379047
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
